[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperlipidemias\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperlipidemias":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,41,74,95,118,146,176,197,219,252,282,307,328,355,378,402],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100641684","phase-1-a-study-to-assess-the-effect-of-hrs-1301-on-the-pharmacokinetics-of-midazolam-and-atorvastatin-in-healthy-participants-100641684",false,"NCT07608705","A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants","An Open-label, Single-arm, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HRS-1301 Tablets on the Pharmacokinetics of Midazolam and Atorvastatin Calcium Tablets in Healthy Participants","Inclusion Criteria:\n\n1. Subjects must be aged ≥ 18 years and ≤ 55 years on the day of signing the informed consent form (ICF);\n2. At screening, body mass index (BMI) must be ≥ 19.0 kg\u002Fm² and \\\u003C 28 kg\u002Fm², with body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females;\n3. Physical examination, vital signs, electrocardiogram (ECG), posteroanterior and lateral chest X-ray\u002FCT, abdominal ultrasound, and laboratory tests (including complete blood count, blood biochemistry, urinalysis, coagulation function, and thyroid function) were normal or abnormal but of no clinical significance;\n4. Female participants must not be pregnant or lactating and must have negative pregnancy test results prior to investigational drug administration; participants must have had no unprotected sexual intercourse within two weeks prior to screening; female participants of childbearing potential and male participants with partners of childbearing potential must agree to comply with the contraception requirements for the duration specified in the protocol and have no plans to donate sperm or eggs;\n5. Subjects who understand the study procedures and methods, voluntarily agree to participate in this trial, and provide written informed consent (ICF).\n\nExclusion Criteria:\n\n1. Subjects with previous medical history or current diagnosis of cardiovascular, respiratory, digestive, urinary, hematological, endocrine, infectious, immunological, malignant neoplastic, neurological, or psychiatric\u002Fmetabolic disorders\u002Fdysfunctions, or any other disease;\n2. Subjects who have gastrointestinal, hepatic, renal, or other known diseases that may affect drug absorption, distribution, metabolism, or excretion, or that may reduce compliance;\n3. Subjects who have experienced severe trauma or undergone major surgery within 3 months prior to screening, or who plan to undergo surgery during the trial period;\n4. Subjects with a history of specific allergies, or with an allergic constitution, or with known hypersensitivity to any component of the investigational drug;\n5. Subjects who have used any medication within 2 weeks prior to screening, or who are still within 5 half-lives of any medication at the time of screening;\n6. Subjects who have participated in any other clinical trial of a drug or medical device within 3 months prior to screening, or who are still within 5 half-lives of a prior investigational drug at the time of screening;\n7. Subjects who have donated blood ≥ 200 mL or experienced significant blood loss (≥ 400 mL) within 4 weeks prior to screening, or who have received a blood transfusion within 8 weeks prior to screening;\n8. Subjects who have received a live (attenuated) vaccine within 4 weeks prior to screening or plan to receive such a vaccine during the trial period.",true,"ALL","18 Years","55 Years",{"count":5,"type":21},"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This phase I study in healthy participants aims to assess the pharmacokinetics of midazolam and atorvastatin when administered alone and in combination with HRS-1301, and to assess the safety of HRS-1301 when administered alone and in combination with midazolam or atorvastatin.",[27],"Hyperlipidemias","RECRUITING","2026-06-15",{"date":31,"type":32},"2026-06-16","ACTUAL",{"date":34,"type":32},"2026-06-08",{"date":36,"type":21},"2026-08",{"name":38,"class":39},"Shandong Suncadia Medicine Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100585556","social-needs-screening-and-chronic-diseases-study-we-care-100585556","NCT06903897","Social Needs Screening and Chronic Diseases Study (WE CARE)","Improving Chronic Disease Outcomes Across the Lifespan by Addressing Structural Racism","Inclusion Criteria:\n\n* Adults and children with diagnosed chronic diseases (hypertension, diabetes mellitus, hyperlipidemia, asthma, or depression) who receive Family Medicine care at one of the study sites.\n* Children (\\\u003C18 years of age) with a diagnosis of asthma.\n* Adult patients (18 years or older) with a diagnosis of diabetes mellitus, hypertension, hyperlipidemia and\u002For depression.\n\nExclusion Criteria:\n\n* In adults (\\>18 years of age), those without one or more of the following diagnoses as recorded by ICD-10 codes in their EHR: hypertension, hyperlipidemia, diabetes mellitus, or depression.\n* In children (\\\u003C18 years of age), those without a diagnosis of asthma.",{"count":49,"type":21},68000,[51],"NA","The goal of this clinical trial is to learn if the implementation of the WE CARE social determinants of health (SDOH) screening and referral intervention with an antiracist lens in primary care settings can lead to a meaningful decrease in chronic disease by monitoring conditions such as hypertension, diabetes, depression, hyperlipidemia, and asthma through clinical measures. The main question it aims to answer is:\n\nDoes the WE CARE SDOH screening and referral intervention applying an antiracism lens informed implementation strategies have the potential to reduce racial\u002Fethnic health inequities in chronic diseases for minoritized patients?",[27,54,55,56,57],"Diabetes","Depression","Pediatric Asthma","Hypertension",[59,60,61,62],"Basic Needs","Social Determinants of Health","Screening tools","Antiracism","2026-05-18",{"date":65,"type":32},"2026-05-22",{"date":67,"type":32},"2025-10-08",{"date":69,"type":21},"2028-09-30",{"name":71,"class":72},"University of Massachusetts, Worcester","OTHER",3,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":40},"100617699","phase-1-a-study-of-hrs-1301-tablets-in-healthy-subjects-and-those-with-impaired-kidney-function-100617699","NCT07322016","A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney Function","A Single-dose, Open-label Phase I Clinical Trial Comparing the Pharmacokinetics, Safety and Pharmacodynamics of HRS-1301 Tablets in Subjects With Mild, Moderate and Severe Renal Insufficiency and Healthy Subjects","Inclusion Criteria:\n\n1. Sign the informed consent before the trial, and fully understand the content, process, and possible adverse reactions of the trial;\n2. Male or female subjects aged 18 to 65 (including 18 and 65);\n3. Body mass index (BMI) ranges from 18 kg\u002Fm2 to 30 kg\u002Fm2 (including 18 and 30),and Male weight ≥ 50.0 kg, female weight ≥ 45.0 kg;\n4. The glomerular filtration rate should meet the following criteria (GFR, mL\u002Fmin): Subjects with mild renal impairment: 60-89 mL\u002Fmin; Subjects with moderate renal impairment: 30-59 mL\u002Fmin; Subjects with severe renal function impairment: 15\\~29 mL\u002Fmin.\n\nExclusion Criteria:\n\n1. Individuals with a specific history of allergies (such as asthma, urticaria, eczema, etc.), or those with an allergic constitution (such as those allergic to any drug or food), or those known to be allergic to any component of the studied drug;\n2. Those with cardiogenic shock, severe conduction obstruction, sick sinus syndrome, heart failure (NYHA grade III-IV), persistent rapid arrhythmia, tortuous ventricular tachycardia or ventricular tachycardia at the pointed point, a history of clinically significant T-wave changes, myocardial infarction, or angina pectoris;\n3. Suffering from malignant tumors, or having a history of malignant tumors within 5 years prior to screening (excluding skin non-melanomas that have been treated without recurrence signs and resected cervical intraepithelial neoplasia);\n4. Those with a history of gastric or intestinal surgery that some researchers believe may affect drug absorption;\n5. Those who have suffered severe trauma or undergone major surgical operations within the three months prior to screening, or who plan to undergo surgery during the trial period;\n6. Those who have participated in any clinical trials of drugs or medical devices within three months prior to screening, or those who are still within five half-lives of the drug before screening (whichever is longer);\n7. Those who have donated blood of ≥ 400 mL within 4 weeks before screening, or have suffered severe blood loss (blood loss ≥ 400 mL), or have received blood transfusion within 8 weeks;\n8. Those who received live (attenuated) vaccines within 4 weeks prior to screening or those who plan to receive them during the trial;\n9. Those with potential difficulties in blood collection and a history of fainting at the sight of needles or blood;\n10. For patients with renal insufficiency,those who have received renal replacement therapy (such as peritoneal dialysis, hemodialysis, etc.) within 3 months prior to the screening or during the expected trial period;\n11. For patients with renal insufficiency，screening individuals with underlying diseases that induce chronic kidney disease within the previous three months and are judged by researchers to be poorly controlled, such as diabetic patients with HbA1c \\> 10%, and hypertensive patients with systolic blood pressure \\> 180 mmHg and diastolic blood pressure \\> 120 mmHg, etc.","65 Years",{"count":83,"type":21},36,[24],"The primary objective of this study is to evaluate pharmacokinetics of HRS-1301 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.",[27],"2026-05-08",{"date":89,"type":32},"2026-05-13",{"date":91,"type":32},"2026-01-13",{"date":93,"type":21},"2026-10",{"name":38,"class":39},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":40},"100520886","penn-medicine-healthy-heart-100520886","NCT06062394","Penn Medicine Healthy Heart","Reducing Atherosclerotic Cardiovascular Disease (ASCVD) Through a Comprehensive Heart Disease Prevention Program (HDPP)","Inclusion Criteria:\n\n* On the Penn Medicine Primary Care Service Line registry\n* Last 2 Blood Pressure readings with Systolic Blood Pressure \\>=140 from any outpatient encounter in the last 12 months AND\n* ASCVD dx OR ASCVD risk score ≥10% OR Diabetes dx OR A1c ≥6.5 in last year OR Diabetes registry OR Last LDL ≥190 in past five years AND\n* Not on a statinor PCSK9, Inclisiran OR on a Low-intensity\u002Fmoderate-intensity statin) with LDL \\>100\n\nExclusion Criteria:\n\n* Patients on PCSK9 inhibitors\n* Documented statin allergy\u002F or intolerance in the EMR\n* Pregnancy\n* Breast feeding\n* Markedly shortened life expectancy including:\n\n  1. metastatic cancer\n  2. hospice\n  3. End Stage Renal Disease\n  4. Congestive Heart Failure\n  5. Dementia\n* Is a non-English speaker requiring a translator\n* Patients who do not have a cell phone","35 Years","80 Years",{"count":105,"type":21},1980,[51],"To leverage access to patients across the primary care network, EPIC tools for identifying eligible patients, and the Way to Health platform to launch and enroll a program that will be evaluated in a clinical trial that is focused on changing patient behavior and powered to detect differences in improving blood pressure and cholesterol over 6 months for Penn Medicine patients in West\u002FSouthwest Philadelphia and Lancaster.",[57,27],"2026-03-10",{"date":111,"type":32},"2026-03-12",{"date":113,"type":32},"2024-03-11",{"date":115,"type":21},"2026-12",{"name":117,"class":72},"University of Pennsylvania",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":126,"phases":4,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":40},"100493302","imaging-the-pathogenesis-of-cerebral-small-vessel-disease-100493302","NCT05703386","Imaging the Pathogenesis of Cerebral Small Vessel Disease","Inclusion Criteria:\n\n* Clinical or radiographic evidence of ischemic stroke\n* One vascular risk factor (hypertension, hyperlipidemia, or diabetes)\n* Evidence of cerebral small vessel disease on MRI\n\nExclusion Criteria:\n\n* Inability to complete 3 research MRI scans over 1.25 years",{"count":125,"type":21},50,"OBSERVATIONAL","Cerebral small vessel disease (CSVD) can lead to vascular cognitive impairment and dementia (VCID). The hallmark of CSVD is the appearance and progression of white matter hyperintensities (WMH) on MRI. The goal of this study it to recruit and follow individuals at risk for WMH progression and use serial MRI scanning to gain insights into the pathogenesis of CSVD.",[129,57,27,54],"Ischemic Stroke",[131,132,133,134,135,136],"Cerebral small vessel disease","Vascular cognitive impairment and dementia","White matter hyperintensities","Blood-brain barrier","Vascular risk factors","Ischemic stroke","2026-03-02",{"date":139,"type":32},"2026-03-03",{"date":141,"type":32},"2022-11-08",{"date":143,"type":21},"2027-03-31",{"name":145,"class":72},"Johns Hopkins University",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":152,"minAge":18,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":174,"locationsCount":40},"100520320","black-impact-the-mechanisms-underlying-psychosocial-stress-reduction-in-a-cardiovascular-health-intervention-100520320","NCT06055036","Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention","Inclusion Criteria:\n\n* The inclusion criteria are: 1) Black men (self-report); 2) adult age 18 years or older; 3) Life's Essential 8 total average score \\\u003C 80; 4) English speaking; and 5) lives in Metropolitan Columbus, Ohio.\n\nExclusion Criteria:\n\n* healthcare provider-imposed limitations on physical activity.","MALE",{"count":154,"type":21},340,[51],"Lower attainment of cardiovascular health (CVH), indicated by the American Heart Association's Life's Simple 7 (LS7; physical activity, diet, cholesterol, blood pressure, body mass index, smoking, glycemia) and Life's Essential 8 (LE8; LS7+sleep) metrics, is a major contributor to Black men having the shortest life-expectancy of any non-indigenous race\u002Fsex group. Unfortunately, a paucity of literature exists on interventions aimed at improving CVH among Black men. The team of clinician scientists and community partners co-developed a community-based lifestyle intervention titled Black Impact: a 24-week intervention for Black men with less-than-ideal CVH (\\\u003C4 LS7 metrics in the ideal range) with 45 minutes of weekly physical activity, 45 minutes of weekly health education, and engagement with a health coach, group fitness trainer, and community health worker. Single-arm pilot testing of the intervention (n=74) revealed high feasibility, acceptability, and retention and a 0.93 (95% confidence interval: 0.40, 1.46, p\\\u003C0.001) point increase in LS7 score at 24 weeks. Secondary outcomes included improvements in psychosocial stress (i.e., perceived stress, depressive symptoms), patient activation, and social needs. Thus, robustly powered clinical trials are needed to determine the efficacy of Black Impact and to evaluate the underlying interpersonal and molecular pathways by which Black Impact improves psychosocial stress and CVH. Thus, the investigators propose a randomized, wait-list controlled trial of Black Impact. This novel, community-based intervention to provide a scalable model to improve CVH and psychosocial stress at the population level and evaluate the biological underpinnings by which the intervention mitigates cardiovascular disease risk. The proposed study aligns with American Heart Association's commitment to addressing CVH equity through innovative, multi-modal solutions.",[158,159,57,160,161,162,163,164,165,27,166,167],"Cardiometabolic Syndrome","Physical Inactivity","Type 2 Diabetes","PreDiabetes","Obesity","Cardiovascular Diseases","Smoking","Sleep","Diet, Healthy","Blood Pressure","2025-09-30",{"date":170,"type":32},"2025-10-06",{"date":172,"type":32},"2023-08-24",{"date":143,"type":21},{"name":175,"class":72},"Ohio State University",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":126,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":40},"100544824","the-role-of-proprotein-convertase-subtilisinkexin-type-9-in-kidney-damage-in-nephrotic-syndrom-100544824","NCT06373913","The Role of Proprotein-convertase-subtilisin\u002FKexin-type 9 in Kidney Damage in Nephrotic Syndrom","PCSK9","Inclusion Criteria:\n\n* 18 years old\n* Patients admitted to the Medical Department and\u002For the Medical Emergency Department, Kolding Sygehus.\n\nExclusion Criteria:\n\n* Refusal to give informed consent\n* Treatment with PCSK9 inhibitors\n* Any acute or chronic condition that would limit the ability of the patient to participate in the study\n* Control group: proteinuria",{"count":184,"type":21},75,"Nephrotic syndrome (NS) is characterized by gross proteinuria (\\>3.5 g\u002Fday), hypoalbuminaemia, edema and often hyperlipidemia. Hyperlipidemia is correlated with increased morbidity and mortality.\n\nThe study aim is to investigate the role of the protein convertase subtilisin\u002Fkexin type 9 (PCSK9) in hyperlipidemia of NS, which has been suggested to play an important role. This is done by testing the following hypotheses:\n\n1. PCSK9 is increased in patients with NS and hyperlipidemia compared to kidney-healthy controls\n2. The level of PCSK9 in plasma correlates to the degree of proteinuria.\n3. PCSK9 i increased in the kidney tissue of patients with NS\n\nThe study will compare plasma levels of PCSK9 in correlation with degree of protein in the urine between test persons with NS and kidney healthy controls. Furthermore the investigators will study the the degree of PCSK9 in the kidney in biopsies obtained from test persons with nephrotic syndrome and test persons without proteinuria.",[27,187],"Nephrotic Syndrome","2025-09-02",{"date":190,"type":32},"2025-09-09",{"date":192,"type":32},"2023-06-01",{"date":194,"type":21},"2028-07-30",{"name":196,"class":72},"Kolding Sygehus",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":204,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":40},"100495911","effect-of-ankascin-568-p-products-regulating-blood-lipid-100495911","NCT05737355","Effect of ANKASCIN 568-P Products Regulating Blood Lipid","Effect of ANKASCIN 568-P Products Regulating Blood Lipid- A Double-blind, Placebo-controlled Clinical Research","Inclusion Criteria:\n\n* Male or Female women over the age of 20 (women of childbearing age should not be pregnant or breastfeeding during the study period).\n* A sane and communicative adult.\n* 18≦BMI≦35.\n* Sub-healthy people with simple dyslipidemia and those who have been judged by the doctor that they do not need to take hypolipidemic drugs for the time being, or those who insist on not taking drugs.\n* Screening criteria Low-density lipoprotein cholesterol (LDL-C): 130\\~190 mg\u002FdL. screening criteria and high-density lipoprotein cholesterol (HLDL-C): below 50 mg\u002FdL.\n* Those without other serious diseases (cancer, heart failure, diabetes, myocardial infarction, liver cirrhosis, moderate to severe liver and kidney dysfunction, stroke, etc.).\n* During the experiment, the daily routine and eating habits should be maintained and not changed deliberately.\n\nExclusion Criteria:\n\n* Triglyceride TG≧500 mg\u002FdL.\n* Blood pressure value: systolic blood pressure ≧ 200 mmHg or diastolic blood pressure ≧ 140 mmHg.\n* Patients with moderate or severe abnormal liver and kidney function (generally referring to serum aminopyruvate converting enzyme (SGPT), serum glutamate phenylacetate transaminase (SGOT) are more than 3 times the upper limit of normal or have been diagnosed Liver cirrhosis, or glomerular filtration rate eGFR≦30 ml\u002Fmin\u002F1.73m2).\n* Pregnant or lactating women.\n* Those who take traditional Chinese medicine mainly based on red yeast rice.\n* Those who have undergone surgery within one month.\n* Those who have serious diseases such as heart, liver, kidney, and hematopoietic system, mentally ill patients who do not meet the inclusion criteria, fail to use the test product according to the regulations so that the efficacy or safety cannot be judged due to incomplete data.","20 Years",{"count":206,"type":21},80,[51],"This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)",[27],"2025-08-21",{"date":212,"type":32},"2025-08-28",{"date":214,"type":32},"2023-04-01",{"date":216,"type":21},"2025-10-31",{"name":218,"class":39},"SunWay Biotech Co., LTD.",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":152,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":230,"conditions":231,"keywords":236,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":40},"100500889","early-phase-1-akkermansia-muciniphilia-and-metabolic-side-effects-of-adt-100500889","NCT05802121","Akkermansia Muciniphilia and Metabolic Side Effects of ADT","The Role of Akkermansia Muciniphilia in Combating the Metabolic Effects of Androgen Deprivation Therapy in Men With Metastatic Prostate Cancer","For inclusion in this study, patients must fulfill all of the following criteria:\n\n1. Men ≥18 years of age with histologically-proven metastatic castration-sensitive prostate adenocarcinoma planned to receive ADT (TNM stage Tany, Nany, M1) (see Appendix I).\n2. Must have baseline imaging with 1) CT of the abdomen, and pelvis and bone scan or 2) PSMA PET scan\n\nPatients fulfilling any of the following criteria are NOT eligible for participation in this study:\n\n1. Age less than 18\n2. Primary neuroendocrine prostate cancer\n3. Treatment with ADT within the year leading up to enrolment\n4. Planned or concurrent use of chromium supplementation for the study duration\n5. Planned or concurrent use of apple cider vinegar supplementation for the study duration\n6. Unable to provide informed consent or unable to understand or read the English language (unless accompanied by an interpreter)\n7. Inadequate liver function (\\>2x upper limit of normal)\n8. Any other condition, chronic disease, or lifestyle factor, that, in the opinion of the Qualified Investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant\n9. Use of antibiotics that cannot be discontinued for a washout period and remain off them for the duration of the trial",{"count":227,"type":21},30,[229],"EARLY_PHASE1","The overriding objectives of this study are:\n\n1. Primary outcomes:\n\n   1. To confirm that administration of oral acetate increases the proportion of A. muciniphilia in the stool samples of patients with metastatic, castration-sensitive prostate cancer compared to a standard of care arm.\n   2. To confirm tolerability and assess for side effects of oral acetate supplementation.\n2. Secondary outcomes:\n\n   1. To determine if increased counts of A. muciniphilia correlate with improved metabolic parameters and improved bone health.",[232,233,162,234,235,27,54],"Prostate Cancer","Metabolic Syndrome","Cardiovascular Morbidity","Bone Diseases",[237,238,239,240,241,242],"prostate cancer","metabolic syndrome","androgen deprivation therapy","microbiome","Akkermansias muciniphilia","cardiovascular disease","2025-08-15",{"date":245,"type":32},"2025-08-20",{"date":247,"type":32},"2025-07-02",{"date":249,"type":21},"2027-06",{"name":251,"class":72},"Western University",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":269,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":40},"100519889","lifestyle-medicine-establishing-clinical-approaches-to-chronic-disease-for-rural-patients-100519889","NCT06049420","Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients","Inclusion Criteria:\n\n* Program admittance will be restricted to patients with 2+ diagnosed diseases that have sufficient evidence for the efficacy of exercise therapy (obesity, hyperlipidemia, metabolic syndrome, polycystic ovarian syndrome, type II diabetes, hypertension, coronary heart disease, heart failure, depression, anxiety)\n* physician referral required\n\nExclusion Criteria:\n\n* no chronic disease diagnosis, lack of physician referral, unwillingness to participate.","64 Years",{"count":260,"type":21},95,[51],"Developed nations worldwide are currently enduring a health crisis, as chronic diseases continue to decrease quality of life and promote additional disease states or even death for much of the population. Rural populations are at a particular disadvantage, as they lack access to health clubs, wellness programs and similar resources that are more available in urban areas. Although pharmaceutical therapies have continued to show therapeutic advancements, the rates of disease onset and death from chronic disease has not seen similar improvements, and in fact continue to worsen. Excitingly, significant evidence has been published demonstrating an affordable, effective treatment to directly treat and prevent these chronic diseases, but few have demonstrated successful implementation of this therapy, which is improved lifestyle. Specifically, physical activity and healthy body composition are powerful therapeutics that have been demonstrated to effectively combat and prevent chronic diseases. Additionally, improving these lifestyle factors are often more effective than pharmaceutical interventions without the wide range of side effects. Unfortunately, barriers exist on multiple tiers in the practice of family medicine that demote the implementation of lifestyle medicine. To better serve patients at risk of, or suffering from chronic disease, the investigators are seeking to establish a lifestyle medicine prescription program for rural West Virginia. This program will provide patient education on the benefits of physical activity, body composition, and help patients identify strategies to implement healthy lifestyle choices that can be sustainable for the long-term. Patients will be advised on local opportunities to increase physical activity (yoga studio, martial arts, fitness facilities, aquatic center, etc.) and provided access to the facilities they are most likely to adhere to regularly. They will also be provided training on exercise techniques, equipment, and facilities to increase familiarity and comfort in these settings.",[162,27,264,57,265,266,267,268,233],"Polycystic Ovary Syndrome","Coronary Heart Disease","Heart Failure","Depression, Anxiety","Type II Diabetes",[270,271,272],"lifestyle","chronic disease","physical activity","2025-07-21",{"date":275,"type":32},"2025-07-25",{"date":277,"type":32},"2025-02-01",{"date":279,"type":21},"2027-09-01",{"name":281,"class":72},"West Virginia School of Osteopathic Medicine",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":40},"100474413","pcsk-9-inhibitor-added-to-high-intensity-statin-therapy-to-prevent-cardiovascular-events-in-patients-with-acs-after-pci-100474413","NCT05457582","PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI","PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study","SHAWN","Inclusion Criteria:\n\n1. The subject, or their legal guardian, must have a clear understanding of the trial's design and treatment procedures. They must provide written informed consent before any trial-specific tests or procedures are conducted.\n2. Both male and female subjects aged ≥18 years.\n3. Subjects who have experienced an ACS and have undergone PCI for culprit lesions (either QFR or FFR \\\u003C 0.8) are eligible. ACS is defined as:\n\n(1) Unstable angina (characterized by rest pain lasting between 5 and 30 minutes or worsening exertional angina accompanied by either transient ST segment depression or elevation, or angiography revealing visually estimated diameter stenosis of 90% or greater, or a ruptured plaque or thrombotic lesion), or (2) Non-ST elevation myocardial infarction, indicated by positive troponin levels consistent with the clinical syndrome and non-ST segment elevation, or (3) ST elevation myocardial infarction, indicated by positive troponin levels consistent with the clinical syndrome and ST-segment elevation.\n\n4\\. Low-density lipoprotein cholesterol levels must meet the following criteria:\n\n1. Low-density lipoprotein cholesterol ≥70 mg\u002FdL (≥1.8 mmol\u002FL) in patients who have been on a stable high-intensity statin regimen for at least 4 weeks before enrollment.\n2. Low-density lipoprotein cholesterol ≥90 mg\u002FdL (≥2.3 mmol\u002FL) in patients who have been on a moderate or low-intensity statin regimen before enrollment.\n3. Low-density lipoprotein cholesterol ≥125 mg\u002FdL (≥3.2 mmol\u002FL) in patients who are statin-naïve or have not been on a stable statin regimen for at least 4 weeks before enrollment.\n\n5\\. Subjects must have at least one culprit lesion for ACS in a major native coronary artery (diameter stenosis \\>70% with a QFR or FFR\\\u003C0.8), and have at least one non-culprit vessel disease (diameter stenosis ≤70% with a QFR or FFR ≥0.8).\n\nExclusion Criteria:\n\n1. Fasting serum triglyceride levels exceeding 400 mg\u002FdL (exceeding 4.52 mmol\u002FL) before randomization.\n2. Coronary artery disease is located within a saphenous vein graft or an arterial graft.\n3. Residual diameter stenosis greater than 50% as determined by visual examination after percutaneous coronary intervention of the culprit lesion.\n4. TIMI (Thrombolysis in Myocardial Infarction) flow less than 3 in the culprit vessel after PCI.\n5. Unstable clinical status, characterized by hemodynamic (including cardiogenic shock) or electrical instability.\n6. Uncontrolled hypertension, indicated by multiple readings with systolic blood pressure (SBP) exceeding 180 mmHg or diastolic blood pressure (DBP) exceeding 110 mmHg.\n7. New York Heart Association (NYHA) Class III or IV, and an already known left ventricular ejection fraction (LVEF) below 30%.\n8. Known history of hemorrhagic stroke in last 180 days before randomization.\n9. Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response that has not been controlled by medications in the past 3 months before screening.\n10. Severe renal dysfunction, defined by an estimated glomerular filtration rate (eGFR) below 30 ml\u002Fmin\u002F1.73m².\n11. Active liver disease or hepatic dysfunction.\n12. Known intolerance to rosuvastatin or any statin.\n13. Known allergy to contrast medium, heparin, aspirin, ticagrelor, prasugrel, or clopidogrel.\n14. Subjects who have previously received PCSK9 inhibitors.\n15. Subjects who have received cholesterol ester transfer protein inhibitors within the past 12 months before enrollment.\n16. Treatment with systemic steroids or systemic cyclosporine within the past 3 months.\n17. Known active infection or major hematologic, metabolic, or endocrine dysfunction, as determined by the Investigator.\n18. Planned non-cardiac surgery within the next 12 months.\n19. Subjects who will not be able to attend the required study visits, as determined by the Investigator.\n20. Currently enrolled in another investigational device or drug study.\n21. History of cancer within the past 5 years, unless adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer.\n22. Estimated life expectancy of less than 12 months.\n23. Female of childbearing potential (age \\\u003C50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy, or hysterectomy.",{"count":291,"type":21},1212,[51],"The primary objective was to evaluate the effect of PCSK 9 Inhibitor (initiated within 4 h from PCI for the culprit lesion) with high-intensity statin treatment, compared to placebo with high-intensity statin treatment, on cardiovascular events (including cardiovascular death, myocardial infarction, stroke, re-hospitalization due to acute coronary syndromes or heart failure, or any ischemia-driven coronary revascularization) in patients with acute coronary syndrome and multiple lesions. Alirocumab was used before June 10, 2025; Tafolecimab has been used from June 10, 2025 onward.",[295,27,296,297],"Acute Coronary Syndrome","Percutaneous Coronary Intervention","Cardiovascular Events","2025-06-10",{"date":300,"type":32},"2025-06-13",{"date":302,"type":32},"2023-03-30",{"date":304,"type":21},"2030-09-30",{"name":306,"class":72},"Nanjing First Hospital, Nanjing Medical University",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":40},"100440442","effects-of-omega-3-pufa-on-lipids-inflammatory-factors-and-body-composition-in-patients-with-hyperlipidemia-100440442","NCT05015348","Effects of Omega-3 PUFA on Lipids, Inflammatory Factors and Body Composition in Patients with Hyperlipidemia","Effects of Omega-3 Polyenoic Acid on Blood Lipid, Inflammatory Factors and Body Composition in Patients with Hyperlipidemia","Inclusion Criteria:\n\n* \\[1\\] Gender and age: male or female, 18 years old and above.\n* \\[2\\] Patients were diagnosed with hyperlipidemia. According to the definition of 2016 guidelines for the prevention and treatment of dyslipidemia in Chinese adults, it meets the clinical diagnostic criteria of hyperlipidemia: hypertriglyceridemia \\[TG≥1.7mmol\u002FL\\]; Or mixed with TC≥5.2mmol\u002FL\\]; Or mixed with LDL-C≥3.4mmol\u002FL\\].\n* \\[3\\] Before the study, the subjects fully understood and voluntarily signed the informed consent form, and fully understood the research content, process and possible adverse reactions.\n* \\[4\\] Those who can eat orally.\n* \\[5\\] Be able to complete the research according to the requirements of the research protocol and obey the arrangements of doctors and researchers.\n\nExclusion Criteria:\n\n* \\[1\\] Those who are receiving lipid-lowering drugs.\n* \\[2\\] Hyperlipidemia caused by secondary causes, such as nephrotic syndrome, hypothyroidism, renal failure, liver disease, systemic lupus erythematosus, glycogen accumulation, myeloma, fat atrophy, acute porphyria, polycystic ovary syndrome, etc; Use diuretics, non cardiac selective β Receptor blockers and glucocorticoids which may cause secondary dyslipidemia.\n* \\[3\\] Patients with severe internal and external diseases, such as heart, liver and kidney dysfunction, acute myocardial infarction, stroke, intracerebral hemorrhage, acute attack of COPD, respiratory failure, etc. in recent 3 months, patients who have undergone surgery in recent 3 months, or any person who is not suitable to participate in this study after clinician evaluation.\n* \\[4\\] Have hemorrhagic disease or bleeding tendency.\n* \\[5\\] Those who have a history of allergy to omega-3 polyenoic acid preparation.\n* \\[6\\] Pregnant and lactating women.\n* \\[7\\] Poor compliance, unable to follow up on time or unable to complete the follow-up of medication.\n* \\[8\\] In the course of diagnosis and treatment, if there is any seriously abnormal metabolism or further intervention is needed, or the patient is no longer suitable for continuing the study through the assessment of the competent physician, he can withdraw from the study.",{"count":315,"type":21},120,[51],"Patients with hyperlipidemia will be allocated into intervention or control group randomly. Participants of intervention group will be provided with Omega-3 PUFA, while participants of control group will be provided with placebo which looked same as the drug of intervention group. During the study, all participants can have nutritional counseling and education for low-fat diet. The lipids, inflammatory factors, weight, and body composition will be assessed and recorded before, at the middle, and end of the study.",[27],"2024-12-30",{"date":321,"type":32},"2025-01-01",{"date":323,"type":32},"2021-12-01",{"date":325,"type":21},"2024-12-31",{"name":327,"class":72},"Peking Union Medical College Hospital",{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":16,"sex":17,"minAge":204,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":22,"phases":337,"briefSummary":338,"conditions":339,"keywords":341,"overallStatus":345,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":4},"100565563","implementation-of-a-peer-leader-facilitated-dyadic-intervention-100565563","NCT06643806","Implementation of a Peer Leader-facilitated Dyadic Intervention","Implementation of a Peer Leader-facilitated Dyadic Intervention to Decrease Cardiovascular Disease Risk Among First Generation Asian Indian Immigrants","Inclusion Criteria:\n\n* community-dwelling first generation Asian Indian (AI) immigrants (in marital dyads) between the ages of 18-70 years of age who can read and write English and are technology literate.\n\nExclusion Criteria:\n\n* AIs not in a marital dyad, those below the age of 20 or above 70 years or those born in the US or visiting the US from India.","70 Years",{"count":206,"type":21},[51],"This Pilot Study Large Application builds upon the results of our prior work to 1) Implement and pilot test a peer leader-facilitated 12-week dyadic intervention (Community Health among Asian Indian immigrants (CHAI) Dyad study) using a cluster randomization design, to decrease CVD risk among first generation AI immigrants; and 2) Assess the feasibility\u002Facceptability of a full-scale intervention. Twenty marital dyads from the site randomly assigned as the intervention site will receive the 12- week peer leader-facilitated dyadic intervention, while 20 dyads from the site randomly assigned as the \"usual care\" control group site will receive a basic cardiovascular lifestyle modification program. Both groups will meet weekly (90 min. classes) for 12 weeks in a hybrid format (a combination of face to face and remote learning). The intervention is designed to address factors that we identified in our previous study as contributing to a syndemic of cardiovascular disease among AI immigrants including acculturation stress, family history and genetic risk, physical inactivity, as well as a high fat, high-carbohydrate, high-calorie diet.",[163,340,27],"Type 2 Diabetes Mellitus in Obese",[342,343,344],"Community based participatory research","Asian Indian immigrants","Acculturation stress","NOT_YET_RECRUITING","2024-10-15",{"date":348,"type":32},"2024-10-16",{"date":350,"type":21},"2025-02",{"date":352,"type":21},"2025-07",{"name":354,"class":72},"Rutgers, The State University of New Jersey",{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":22,"phases":363,"briefSummary":364,"conditions":365,"keywords":366,"overallStatus":345,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":40},"100558452","multi-center-clinical-study-on-the-lipid-lowering-efficacy-and-safety-of-menggongzi-tibetan-tea-special-drink-100558452","NCT06551298","Multi Center Clinical Study on the Lipid-lowering Efficacy and Safety of Menggongzi Tibetan Tea Special Drink","Inclusion Criteria:\n\n1. Meets the diagnostic criteria for hyperlipidemia: total cholesterol (TC) ≥ 6.20mmol\u002FL, triglycerides (TG) ≥ 2.30 mmol\u002FL. If one of the above blood lipid indicators is abnormal, it can be included in this study;\n2. Age ≥ 18 years old, gender not limited;\n3. The patient is willing to follow the research protocol and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Atherosclerotic cardiovascular disease (ASCVD) patients;\n2. Diabetes patients;\n3. Severe hypercholesterolemia (TC\\>8 mmol\u002FL or LDL-C ≥ 4.9 mmol\u002FL) or severe hypertriglyceridemia (TG ≥ 5.6 mmol\u002FL);\n4. Secondary hyperlipidemia;\n5. Individuals with a family history of primary hypercholesterolemia;\n6. Active liver disease or unexplained persistent elevation of serum transaminases (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)\\>2-fold upper limit of normal (ULN));\n7. The estimated glomerular filtration rate (eGFR) is less than 30 mL\u002Fmin\u002F1.73m2;\n8. Creatine kinase (CK)\\>3 times ULN;\n9. Individuals who have used any lipid-lowering drugs within the past month; 10）Individuals allergic to Tibetan tea and atorvastatin calcium;\n\n11\\) Individuals with combined mental illnesses or malignant tumors; 12) Pregnant and lactating women; 13) Researchers consider patients who are not suitable for inclusion in the study.",{"count":362,"type":21},129,[51],"About 179 million people die from cardiovascular disease each year, accounting for approximately 31% of global deaths. It is expected that this number will exceed 236 million by 2030, and the economic burden caused by this disease is increasing year by year.At present, the number of people suffering from cardiovascular diseases in China is as high as 330 million, and the mortality rate accounts for more than 40% of the total deaths caused by diseases, and is in a continuous upward trend.Long term dyslipidemia will increase the incidence rate and mortality of atherosclerotic diseases.Tibetan tea contains catechins, caffeine, amino acids, vitamins, and various mineral components, which have significant effects in reducing cholesterol, improving carbohydrate metabolism, lowering blood sugar, losing weight, softening human blood vessels, and other aspects.At present, there are no research reports on the lipid-lowering effect of Mongolian Gongzi Tibetan Tea Special Drink, and most studies on the lipid-lowering effect of Tibetan Tea are animal experiments or clinical observational studies. Therefore, this study intends to use a randomized controlled trial to explore the lipid-lowering efficacy and safety of Mongolian Gongzi Tibetan Tea Special Drink in patients with hyperlipidemia.",[27],[27,367,368],"Tibetan tea","Atorvastatin","2024-09-23",{"date":371,"type":32},"2024-09-25",{"date":373,"type":21},"2024-10-01",{"date":375,"type":21},"2025-08-08",{"name":377,"class":72},"The First Affiliated Hospital with Nanjing Medical University",{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":385,"minAge":18,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":126,"phases":4,"briefSummary":388,"conditions":389,"keywords":391,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":40},"100447193","bempedoic-acid-pregnancy-surveillance-program-100447193","NCT05103254","Bempedoic Acid Pregnancy Surveillance Program","A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Women Exposed to Bempedoic Acid or Bempedoic Acid\u002FEzetimibe Fixed Combination Drug Product (FCDP) During Pregnancy","Inclusion Criteria:\n\nExposure to at least 1 dose of bempedoic acid or bempedoic acid\u002Fezetimibe FCDP at any time during pregnancy (from first day of last menstrual period \\[LMP\\] to pregnancy outcome\n\nExclusion Criteria:","FEMALE",{"count":387,"type":21},20,"Bempedoic acid pregnancy surveillance program",[390,27],"Pregnancy",[392],"bempedoic acid","2024-05-15",{"date":395,"type":32},"2024-05-17",{"date":397,"type":32},"2021-09-01",{"date":399,"type":21},"2032-05",{"name":401,"class":39},"Esperion Therapeutics, Inc.",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":409,"enrollmentInfo":410,"targetDuration":412,"studyType":126,"phases":4,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":40},"100457856","integrated-diagnosis-and-treatment-of-ckd-on-outcomes-100457856","NCT05242055","Integrated Diagnosis and Treatment of CKD on Outcomes","A Prospective, Cohort, and Observational Study of the Effect of Integrated Diagnosis and Treatment of Chronic Kidney Disease (CKD) on Clinical Outcomes in Real World Clinical Practice","Inclusion Criteria:\n\n* ≥18 years old;\n* Voluntarily signed informed consent;\n* Patients who are estimated to develop CKD.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or ≥100 years;\n* Unable to comply with the procedures stipulated in this study;\n* Estimated follow-up time ≤6 months.","100 Years",{"count":411,"type":21},1000,"5 Years","Objective: To establish a study cohort and follow up of patients with CKD in our hospital, and evaluate the status of integrated CKD diagnosis and treatment according to guidelines in the real world, as well as the clinical prognosis of patients with different stratification.\n\nMethods: By establishing a cohort of 1000 patients with CKD and conducting long-term follow-up, integrated diagnosis and treatment for CKD was performed, namely: Regular monitoring, control of blood pressure, blood glucose, blood lipid, correction of anemia, minerals - bone metabolic abnormalities, malnutrition, acid and alkali, and electrolyte disorder, diet and exercise, such as the guidance of integrated management, non intrusive, observational studies, prospective cohort were analyzed retrospectively, describe the implementation of the integration of diagnosis and treatment, chronic kidney disease (CKD) Stratified analysis and risk factor analysis were performed for cardiovascular disease and other main endpoint events, so as to objectively reflect the status of integrated treatment of CKD and provide data support for continuous quality improvement of CKD diagnosis and treatment and improvement of clinical prognosis of patients.",[415,57,416,27,417,418,419],"Chronic Kidney Diseases","Hyperglycemia","Anemia","Chronic Kidney Disease-Mineral and Bone Disorder","Malnutrition","2022-05-02",{"date":422,"type":32},"2022-05-06",{"date":424,"type":32},"2022-02-01",{"date":426,"type":21},"2026-12-31",{"name":428,"class":72},"Capital Medical University"]